Recent News

• 02.11.2026 - Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
• 02.11.2026 - Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
• 02.05.2026 - Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
• 02.05.2026 - Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
• 01.26.2026 - Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
• 01.26.2026 - Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
• 01.09.2026 - Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
• 01.09.2026 - Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
• 01.08.2026 - Akari Therapeutics to Present at the 2026 Biotech Showcase
• 01.08.2026 - Akari Therapeutics to Present at the 2026 Biotech Showcase

Recent Filings

• 02.02.2026 - DEF 14A Other definitive proxy statements
• 01.29.2026 - EFFECT Notice of Effectiveness
• 01.23.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 01.22.2026 - PRE 14A Other preliminary proxy statements
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities